Composition claims, patents

A peculiarity of the processes described in the patents is that all of them use isobutane-rich conditions, with isobutane-to-dioxygen molar ratios between 2 (for processes that include a relatively low concentration of inert components) and 0.8, and so closer to the stoichiometric value 0.5 (for those processes where a large amount of inert components is present). This is shown in Figure 14.1, which reports in a triangular diagram the feed composition claimed by the various companies, with reference to the flammability area at room temperature. Low isobutane conversions are achieved in all cases, and recirculation of unconverted isobutane becomes a compulsory choice. For this reason, Sumitomo claimed the oxidation of CO to CO2 (contained in the effluents from the oxidation reactor) in... 

Each claim in an issued U.S. patent application will be numbered, and each claim is exactly one sentence long.8 The structure of a typical claim contains three parts, which are, in the order of their usual appearance, the preamble, the transition, and the claim body (Figure 5.4 identifies the three parts of the composition claim 1 and the process claim 2). 

Patent of England M987448, Stabilized polymeric compositions. Claimed- 12.01.1962. Published - 1966. 

Patents of pharmaceutical inventions contain one or more of five types of claims. They pertain to individual compounds, other compositions of matter, chemical processes, methods of use, or medical devices. Formulations like creams or tablets exemplify the subject matter of some composition claims, which may include the active ingredient as well as other substances... 

Only in 1970, John E. Franz at Monsanto observed its outstanding herbi-cidal activity (Fig. 8.11). Monsanto registered the use of substance CP67573 worldwide as a herbicide, without however being able to claim patent protection of the compound itself ( composition of matter ). It is remarkable that Henri Martin s substance was developed as a commercial product without any structural modification. 

TABLE 16.1 SPS/Nylon Blend Compositions Claimed in Patents... 

Patents claiming specific catalysts and processes for thek use in each of the two reactions have been assigned to Japan Catalytic (45,47—49), Sohio (50), Toyo Soda (51), Rohm and Haas (52), Sumitomo (53), BASF (54), Mitsubishi Petrochemical (56,57), Celanese (55), and others. The catalysts used for these reactions remain based on bismuth molybdate for the first stage and molybdenum vanadium oxides for the second stage, but improvements in minor component composition and catalyst preparation have resulted in yields that can reach the 85—90% range and lifetimes of several years under optimum conditions. Since plants operate under more productive conditions than those optimum for yield and life, the economically most attractive yields and productive lifetimes maybe somewhat lower. 

A number of azetidine-based compounds have been disclosed in patent applications from Aventis Pharma for CBi-modulated treatment of diseases such as obesity, Parkinson s disease, schizophrenia, respiratory and neurological diseases [330-334]. Compound (556) was specifically claimed for use in two formulation patent applications [330, 331] for a stable semi-solid composition and oral emulsion composition, respectively. The optional coadministration of an agent that activates norepinephrinergic and se-rotoninergic neurotransmission (for example, sibutramine) or dopaminergic neurotransmission was also claimed for the treatment of obesity. The optional use of a dopamine agonist (for example, levodopa) was claimed... 

The foregoing reaction scheme had been described in a patent issued in 1934 to Clemmensen (9), who prepared certain organic esters of thiophosphoric acid embodying both aromatic and aliphatic radicals. These esters are claimed as new compositions of matter useful as fire retardants. Parathion itself is not specifically described in the patent. 

---